Stone Crest Wealth Management, Inc. Viridian Therapeutics, Inc.\De Transaction History
Stone Crest Wealth Management, Inc.
- $153 Billion
- Q4 2024
A detailed history of Stone Crest Wealth Management, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Stone Crest Wealth Management, Inc. holds 25,859 shares of VRDN stock, worth $434,172. This represents 0.32% of its overall portfolio holdings.
Number of Shares
25,859
Previous 27,593
6.28%
Holding current value
$434,172
Previous $628 Million
21.03%
% of portfolio
0.32%
Previous 0.46%
Shares
5 transactions
Others Institutions Holding VRDN
# of Institutions
193Shares Held
78.5MCall Options Held
575KPut Options Held
441K-
Black Rock Inc. New York, NY4.77MShares$80.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$77.2 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$65.2 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$63 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$57.9 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $670M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...